Introduction
============

*Cronobacter* infections are associated with adults and infants ([@B5]; [@B28]; [@B2]; [@B20]). Nevertheless, infections of premature neonates are of particular concern are due to their high lethality rate of between 40 and 80% ([@B36]). The clinical manifestation of this pathogen in infants is mainly meningitis, septicemia, and necrotizing enterocolitis ([@B48]; [@B59]; [@B4]; [@B26]) although diarrheal and urinary infections have also been observed ([@B23]).

From 2003 to 2009, 544 cases of *Cronobacter* spp. infection were identified in 6 states of the United States, especially among children \<5 years of age ([@B51]), indeed, *Cronobacter* is the genus that is the most commonly involved in cases of illness associated mainly with the consumption of contaminated powdered infant formula (PIF) rehydrated ([@B17], [@B18]) although, additional possible reservoirs from preparation utensils and the environment have been recognized ([@B22]; [@B55]; [@B28]) and contaminated expressed breast milk, where *C. malonaticus* strain was isolated from a breast abscess ([@B6]). Additionally, *C. sakazakii* has been isolated from the enteral feeding tubes of neonates not fed reconstituted infant formula ([@B29]).

There are recommended biochemical methods to identify *Cronobacter* spp. (Api20E, ID32E, BIOLOG microarray, Vitek 2 System), but these can only be used for presumptive identification and they can have accuracy level as low as 43% ([@B10]; [@B37]; [@B30]). Several PCR primers have been proposed to identify members of the genus *Cronobacter* by amplifying specific sequences of variable and conserved regions of the 16S rRNA of the bacteria ([@B44]; [@B27]). Specific primers for the *rpoB* gene encoding the β region of the polymerase enzyme have been proposed for identifying *Cronobacter* species, but have not taken into account changes in the taxonomy of the species, giving false positive results with some *Enterobacter* species ([@B31]; [@B30]).

[@B3] developed a 7-loci multilocus sequence typing (MLST) scheme for *Cronobacter* speciation and genotyping. The MLST scheme has an open access database^[1](#fn01){ref-type="fn"}^ that contains \>2,400 strains and \>350 whole genomes along with corresponding metadata and updates according to changes in taxonomy. This approach has led to the recognition of clonal complexes (CC) within the *Cronobacter* genus. Of special significance is the recognition of the *Cronobacter sakazakii* CC4 pathovar which is strongly associated with neonatal meningitis cases ([@B35]; [@B56]; [@B25]; [@B21]; [@B20]).

[@B31] provided the re-evaluation of a previous study done by [@B16] of *C. sakazakii* outbreak caused by consuming contaminated reconstituted PIF in Mexico, which had used phenotyping and *rpoB* PCR probe method to identify the isolates, whereas [@B31] used DNA sequencing, and showed that the strains were *E. hormaechei* and *Enterobacter* spp. (undesignated species), demonstrating for the first time, the possible transmission of *Enterobacter* from PIF to infants ([@B31]). This possible transmission suggests that these organisms may pose a risk to infants consuming rehydrated PIF ([@B31]). In fact, this risk was estimated by [@B50] in a risk based assessment under a probabilistic approach of reconstituted PIF contaminated with different inoculum size of *Cronobacter*, differing heat treatment to prepare the PIF and storage temperature.

Important aspects to be considered in the severity and prognosis of *Cronobacter* infection are the presence of antibiotic-resistance ([@B9]; [@B39]; [@B62]), and virulence factors ([@B57]). Such virulence factors can include iron acquisition and the invasiveness and adhesion in cell lines such as HEp-2 and CaCo-2 ([@B49]; [@B45]; [@B24]; [@B1]).

The aim of this work was to evaluate and compare the virulence and antibiotic resistance profiles of the *Cronobacter sakazakii* and *Enterobacter* spp. involved in the diarrheic hemorrhagic outbreak in Mexico in 2011.

Materials and Methods {#s1}
=====================

Bacterial Strains
-----------------

All bacterial strains (*n* = 24) had been isolated and identified according to 7-loci MLST as previously described ([@B31]) (**Figure [1](#F1){ref-type="fig"}**). They had been recovered from PIF (*n* = 14), fecal material (*n* = 6), and the PIF preparation area (*n* = 4).

![The phylogenetic tree of fusA sequencing of *Cronobacter sakazakii, Enterobacter hormaechei*, and *Enterobacter* spp. The tree with the highest log likelihood (--1450.2262) is shown. Initial tree using the Maximum Composite Likelihood (MCL). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis involved 24 nucleotide sequences. Codon positions included were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. There were a total of 401 positions in the final dataset and analyses were conducted in MEGA7.](fmicb-09-02206-g001){#F1}

Sequencing of fusA Gene
-----------------------

The methodology described by [@B3] was followed using PCR CORE Kit QIAGEN (Cat No. 201225) solutions. Amplified products were sent to MACROGEN in Korea for sequencing. The sequenced products were analyzed with the Gentle software and later aligned with the ClustalW software. A phylogenetic tree was constructed using the maximum likelihood method with the MEGA7 software. Identification was performed with the free access online database <https://pubmlst.org/cronobacter/> and BLASTn (NCBI).

Antibiotic Resistance Profile
-----------------------------

The antibiograms of 24 strains were performed by the disk diffusion method ([@B11]). Disks with 12 commercial antibiotics were used (Bio-Rad^TM^, United States): ampicillin (10 μg), amikacin (30 μg), levofloxacin (5 μg), cephalothin (30 μg), cefotaxime (30 μg), ceftriaxone (30 μg), chloramphenicol (30 μg), gentamicin (10 μg), netilmicin (30 μg), nitrofurantoin (300 μg), cefepime (30 μg), and sulfamethoxazole-trimethoprim (25 μg). The characterization of the strain resistance/susceptibility profiles was determined by measuring the inhibition area and interpreting the diameters according to the manufacturer's instructions. *Escherichia coli* ATCC 25922 was used as a reference.

Virulence Determination of *Cronobacter* and *Enterobacter* spp.
----------------------------------------------------------------

### Adherence Assay

HEp-2 cells were cultured in Eagle's minimal medium (MEM) (In Vitro, Mexico) supplemented with 10% fetal bovine serum (FBS) (Gibco, United States) and without antibiotics. The cells were prepared in T75 cm^2^ flasks (Sarstedt, Germany) and grown for 24 h at 37°C and 5% CO~2~. Upon reaching confluency, cells were disaggregated with 0.25% trypsin (In Vitro, Mexico) and sown into 24 well plates from a 1 ml suspension containing 2.5 × 10^6^ HEp-2 cells per ml (Sarstedt, Germany). The monolayers with 70--80% confluency were washed three times with phosphate-buffered saline (PBS) and 900 μl of MEM were added. Isolates were previously cultured overnight in 1% tryptone, and 100 μl bacterial suspensions (10^8^ cells per ml) were added to each well. Plates were incubated for 3 h at 37°C and 5% CO~2~. For quantitative assays, bacteria were removed by adding 1 ml 0.1% Triton X-100 (Amresco, United States), and serial 10-fold dilutions were plated onto tryptone soy agar (TSA) to determine the colony-forming units (CFU) of bacteria bound to HEp-2 cells. Triplicate assays were performed. Enteroaggregative *E. coli* O42 (EAEC) was used as the positive control. *Escherichia coli* K-12 HB101 was the negative control ([@B13]). This assay was repeated three times and the results were expressed as the means ± SD of the data.

### Invasion Assays

The HEp-2 cell lines were prepared according to the procedure described in the adherence assay section. After 3-h incubation, the infected monolayers were washed three times with PBS and incubated with 1 ml MEM with lysozyme 300 μg/ml and gentamycin 100 μg ml^-1^ (In Vitro, Mexico). Samples were washed once with PBS. For quantitative assays, cells were washed three times with PBS, detached with 1 ml 0.1% Triton X-100 and plated on TSA. Invasion frequencies were calculated as the number of bacteria surviving incubation with gentamycin divided by the total number of bacteria present in the absence of this antibiotic (bacterial adherence). Enteroinvasive *E. coli* 1192 and *E. coli* HB101 (K-12) were used as positive and negative controls, respectively. This assay was repeated three times and the results were expressed as the means ± standard deviation of the data ([@B13]).

Results and Discussion
======================

This study is an extension of a previous study by [@B16] and [@B31], who suggested that, after the fusA sequence analysis, isolates from the outbreak in Mexico 2011 were a mixture of *C. sakazakii*, *Enterobacter hormaechei*, and *Enterobacter* spp. This was also corroborated by the phylogenetic analysis that clearly showed differences with other strains (**Figure [1](#F1){ref-type="fig"}**). Currently, the fusA sequencing method enables higher speciation accuracy because it follows the whole genome phylogeny and adjusts to taxonomic changes ([@B21]; [@B63]; [@B2]; [@B31]).

Several studies have confirmed that *Cronobacter* strains can be effectively eliminated by antibiotics, however, prolonged use of antibiotics, inappropriate dose, quantity and length of application are undesirable as it may result in the development of *Cronobacter* antibiotic resistance ([@B52]; [@B43]; [@B14]; [@B38]). Therefore, it is interesting to determine some degree of association in the resistance profiles among strains from food products, environment, and fecal matter of colonized individuals exhibiting or not exhibiting symptoms or from a foodborne outbreak. This aspect is considered part of the objective of the present study because the strains were isolated from PIF, surfaces on which PIF was prepared (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**), and fecal matter of infants associated to an outbreak occurred in Mexico ([@B16]). This evaluation enables the design of treatment strategies for exposed individuals, especially those who are hypersensitive such as infants and the elderly. Although, there is considerable speculation about the source of PIF contamination. Some researchers suggest that the sources are either the environment of the production plants ([@B12]; [@B32]; [@B15]; [@B33]) or the ingredients (i.e., starch) used to prepare the PIF, which are the probable vehicles of transmission ([@B17]; [@B34]; [@B60]). The [@B17], [@B18]) risk assessments on the microbiological safety of infant formula also recognized that other members of *Enterobacteriaceae* were recoverable from PIF and could put infants at risk even though no confirmed cases had been confirmed at that time.

In our study, the 24 strains were identified as *C. sakazakii* (5), *Enterobacter hormaechei* (3), and *Enterobacter* spp. (16). In general, 83% (20/24) of the isolated strains were resistant to 1--7 antibiotics. Eight percent (2/24) were resistant to 5 antibiotics and 37% (9/24) resistant to 3 antibiotics. Sixty-five percent (16/24) of the resistant strains were isolated from PIF (**Table [1](#T1){ref-type="table"}**).

###### 

Resistant antibiotics of isolated strains by source and species.

  N° antibiotics tested   Species   N° of resistant strains                                      
  ----------------------- --------- ------------------------- ---- ---- ---- ---- ---- ---- ---- ----
  1                       3         --                        --   --   --   --   1    --   1    5
  2                       1         --                        --   --   --   --   3    1    --   6
  3                       --        --                        --   1    --   --   3    1    1    6
  4                       --        --                        --   --   --   --   \-   --   1    1
  5                       --        --                        --   --   --   1    --   --   --   1
  7                       --        --                        --   --   --   --   --   --   1    1
  Total                   4         --                        --   2    --   1    7    2    4    20

Eighty percent of *C. sakazakii* (4/5) strains were resistant to cephalothin (**Table [2](#T2){ref-type="table"}**). It is important to assess the antibiotic resistance profile of *Cronobacter* spp., associated to those product (PIFs and infant products) consumed by high risk population whose are immunologically vulnerable. [@B47] reported that of 33 *C. sakazakii* strains isolated in the environment, 51% were resistant to cephalothin. [@B41] also reported a moderate resistance to cephalothin in isolated strains in a case of meningoencephalitis.

###### 

Resistant antibiotics profile of *Cronobacter sakazakii*, *E. hormaechei*, and *Enterobacter* spp.

  Species               Strains   Source                            LEV (5 μg)   FEP (30 μg)   CF (30 μg)   CTX (30 μg)   SXT (25 μg)   AM (10 μg)   CRO (30 μg)   NF (300 μg)   NET (30 μg)   GE (10 μg)   AK (30 μg)   CL (30 μg)
  --------------------- --------- --------------------------------- ------------ ------------- ------------ ------------- ------------- ------------ ------------- ------------- ------------- ------------ ------------ ------------
  *C. sakazakii*        8710      PIF -- México                     S            S             R            S             S             S            S             S             S             S            S            S
  *C. sakazakii*        8718      PIF -- México                     S            S             R            S             S             S            S             S             S             S            S            S
  *C. sakazakii*        8731      PIF -- México                     S            S             R            S             S             I            S             S             S             S            S            S
  *C. sakazakii*        8733      PIF -- México                     S            S             R            S             S             R            S             I             S             S            S            S
  *C. sakazakii*        8756      Sink washing area (bottles)       S            S             I            S             S             S            S             S             S             S            S            S
  *E. hormaechei*       8701      Fecal matter                      S            S             R            R             S             R            R             R             S             S            S            S
  *E. hormaechei*       8724      PIF -- United States              S            S             R            S             S             R            S             R             S             S            S            S
  *E. hormaechei*       8735      PIF -- México                     S            S             R            S             S             R            S             I             S             S            S            S
  *Enterobacter* spp.   8700      Fecal matter                      S            S             R            R             S             R            R             I             R             R            I            R
  *Enterobacter* spp.   8702      Fecal matter                      S            S             R            I             S             R            S             R             S             S            S            R
  *Enterobacter* spp.   8704      Fecal matter                      S            S             S            S             S             S            S             S             S             S            S            S
  *Enterobacter* spp.   8705      PIF -- United States              S            S             R            I             S             R            S             R             S             S            S            S
  *Enterobacter* spp.   8706      Fecal matter                      S            S             I            S             S             R            S             R             S             S            S            S
  *Enterobacter* spp.   8707      PIF -- United States              S            S             S            I             S             S            I             I             S             S            S            S
  *Enterobacter* spp.   8708      PIF -- United States              S            S             R            I             S             S            I             R             S             S            S            S
  *Enterobacter* spp.   8709      Fecal matter                      S            S             R            S             S             R            S             R             S             S            S            S
  *Enterobacter* spp.   8714      Refrigerator try                  S            S             R            S             S             S            S             S             S             S            S            S
  *Enterobacter* spp.   8715      Fecal matter                      S            R             R            R             S             I            I             S             S             S            S            S
  *Enterobacter* spp.   8716      PIF -- United States              S            S             R            I             S             S            I             R             S             S            S            S
  *Enterobacter* spp.   8717      PIF -- United States              S            S             R            S             S             S            S             R             S             S            S            S
  *Enterobacter* spp.   8720      PIF -- México                     S            S             R            S             S             R            S             R             S             S            S            S
  *Enterobacter* spp.   8721      PIF -- United States              S            S             R            S             S             S            S             R             S             S            S            S
  *Enterobacter* spp.   8736      PIF -- México                     S            S             R            S             S             I            S             S             S             S            S            S
  *Enterobacter* spp.   8740      Washing area table                S            S             R            S             S             R            S             R             S             S            S            S
  *Enterobacter* spp.   8741      Preparation area handles access   S            R             R            R             S             I            I             S             S             S            S            S
  *Enterobacter* spp.   8744      Preparation area table            S            S             S            S             S             S            S             S             S             S            S            S
  *Enterobacter* spp.   8766      Sink washing area                 S            S             S            S             S             S            S             S             S             S            S            S
  *Enterobacter* spp.   8767      Fecal matter                      S            S             S            S             S             S            S             R             S             S            S            S
  *Enterobacter* spp.   8770      Refrigerator handles              S            S             I            S             S             S            S             S             S             S            S            S
  *Enterobacter* spp.   8775      PIF -- United States              S            R             I            R             R             R            I             S             S             S            S            S

LEV Levofloxacin, FEP Cefepime, CF Cephalothin, CTX Cefotaxime, SXT trimethoprim-Sulfamethoxazole, AM Ampicillin, CRO Ceftriaxone, NF Nitrofurantoin, NET Netilmicin, GE Gentamicin, AK Amikacin, CL Chloramphenicol. R: resistant; I: intermediate; S: susceptible.

For *E. hormaechei*, 100% (3/3) were resistant to cephalothin and ampicillin, 33% (1/3) to cefotaxime and ceftriaxone, and 66% (2/3) to nitrofurantoin. The *Enterobacter* spp. strains were resistant to cephalothin and ampicillin. The resistance values for ampicillin and cephalothin are higher than those previously reported ([@B40]; [@B47]). [@B42] reported isolated strains were resistant to the first and second cephalosporin generation. The same situation was found in the present study with the *Cronobacter sakazakii* and *Enterobacter* strains isolated from PIF, milk kitchen surfaces, and fecal matter. Resistance was 26% (4/16) for cefotaxime, 13% (2/16) for ceftriaxone, and 26% (4/16) for cefepime (**Table [2](#T2){ref-type="table"}**). This suggests that ß-lactamase production should be further monitored as recommended by the [@B19], especially since the resistant strains were isolated from PIF. [@B9] analyzed *Cronobacter sakazakii* strains from an outbreak with fatalities in a neonatal intensive care unit in France; they found one pulsotype that was associated with the three fatal cases. These were later shown to be the pathovar *C. sakazakii* CC4 ([@B35]; [@B46]). In addition, two of these isolates had extended-spectrum ß-lactamase activity. A recent study evaluated the antimicrobial and desiccation resistance of *Cronobacter sakazakii* ([@B8]), and *Cronobacter malonaticus* isolates from powdered infant formula and processing environments showed that the 70 *Cronobacter* strains, representing 19 sequence types, were susceptible to the most of the antibiotics except for amoxicillin-clavulanate, ampicillin, and cefazolin ([@B14]) which is in accordance with our results.

Our findings indicate that hospitalized infants were unpurposed and accidentally exposed to *Cronobacter* and *Enterobacter* spp. for 2 months. This fact could increase the susceptibility to suffer an infection by this pathogen, especially if this pathogen has a variety of virulence factors which aid in tissue adhesion, invasion and host cell injury. In addition, the results of this study indicate the hospitalized infants were unpurposed and accidentally exposed to *Cronobacter* and *Enterobacter* spp. which were able to adhere and invade human cells (HEp-2 cell line) *in vitro.* This was shown using twelve selected strains which had been isolated from PIF, work surfaces, and fecal matter (**Figure [2](#F2){ref-type="fig"}**). Due to funding limitations it was impossible to carry out more strains analysis.

![Adherence **(A)** and invasion frequencies **(B)** of the HEp-2 cell line to *C. sakazakii*, *E. hormaechei*, and *Enterobacter* spp.](fmicb-09-02206-g002){#F2}

Adherence is one of the events that enables bacteria to colonize and invade the host cells; it is a property associated with bacterial pathogenesis, especially of intracellular pathogens ([@B53]; [@B13]). In our study, adherence mean values in *Cronobacter* spp., *Enterobacter hormaechei*, and *Enterobacter* spp. HEp-2 cells were 22, 23, and 19 × 10^4^ CFU/mL and with no significant differences among them (*p* \> 0.05). Mean invasion values were 3.3, 5.2, and 2.5%, respectively; *E. hormaechei* (*p* = 0.001) was significantly more invasive than *C. sakazakii*. In general, 100% of the evaluated strains had adherence capacity and 75% were invasive in HEp-cells; these values were similar to the results reported by [@B45] and [@B57].

[@B13] found five species of *Cronobacter* spp. (*C. sakazakii, C. malonaticus, C. dublinensis, C. muytjensii*, and *C*. genomospecies (current *universalis*), all of which had the capacity to adhere to HEp-2 cell lines. The *C. sakazakii* strains from a human source exhibited higher adherence values compared to strains of the same species isolated from other sources. Furthermore, when the invasion capacity of *C. sakazakii* was evaluated, it was found that 35% of the isolates were invasive and apparently more efficient than the other evaluated *Cronobacter* spp. species.

The *C. sakazakii* and *E. hormaechei* strains evaluated in our study were invasive; however, *Enterobacter* spp. only had 33% of invasive strains, which is of concern because the virulence trait is in isolated PIF strains. Reports of several outbreaks of sepsis in neonatal intensive care units in Brazil and the United States ([@B7]; [@B57]) have shown that *E. hormaechei* is clinically significant, indeed an outbreak of *E. hormaechei* occurred among premature infants in the intensive care nursery (ICN) at the Hospital of the University of Pennsylvania between November 29, 1992 and March 17, 1993 ([@B61]).

*Cronobacter* species adhered to HEp-2, Caco-2 and brain microvascular endothelial cells, producing two distinctive adherence patterns, a diffuse and a localized adhesion ([@B45]; [@B13]). Moreover, it has been suggested that the outer membrane proteins OmpA and OmpX from *C. sakazakii* are involved in basolateral invasion of human enterocyte-like Caco-2 and intestinal epithelial cells ([@B58]; [@B54]).

In conclusion, all isolated strains showed resistant to more than one antibiotic (cephalothin, ampicillin, cefotaxime, and ceftriaxone) independent of the source of isolation. In addition, *C. sakazakii* strains isolated from PIF were significantly more invasive than *Enterobacter* spp. Individually; *E. hormaechei* was more invasive than *C. sakazakii* and *Enterobacter* spp.

The knowledge generated in the present work can be used to complement existing information to better control *Cronobacter* and *Enterobacter* spp. contamination in PIF production, prevent its transmission, and improve infant food safety. This information should support regulatory and health authorities in their microbial surveillance measures and improve neonatal and infant health.
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Milk kitchen floor plan: **(A)** PIF bottles preparation area (sterile), and **(B)** Washing and disinfection area.
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Click here for additional data file.
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